BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tapper EB, Loomba R. Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD. Nat Rev Gastroenterol Hepatol 2018;15:274-82. [PMID: 29463906 DOI: 10.1038/nrgastro.2018.10] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 14.8] [Reference Citation Analysis]
Number Citing Articles
1 Lupsor-Platon M, Serban T, Silion AI, Tirpe A, Florea M. Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography. Cancers (Basel) 2020;12:E2778. [PMID: 32998257 DOI: 10.3390/cancers12102778] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Carvalho-Furtado ACL, Carvalho-Louro DM, Regattieri NAT, Rodrigues MP, Montenegro MLRN, Ferro AM, Pirangi PS, Naves LA. Transient Elastography and Controlled Attenuation Parameter (CAP) in the Assessment of Liver Steatosis in Severe Adult Growth Hormone Deficiency. Front Endocrinol (Lausanne) 2019;10:364. [PMID: 31275240 DOI: 10.3389/fendo.2019.00364] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
3 Paruk IM, Pirie FJ, Motala AA. Non-alcoholic fatty liver disease in Africa: A hidden danger. Glob Health Epidemiol Genom. 2019;4:e3. [PMID: 31019719 DOI: 10.1017/gheg.2019.2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wood-Trageser MA, Lesniak AJ, Demetris AJ. Enhancing the Value of Histopathological Assessment of Allograft Biopsy Monitoring. Transplantation 2019;103:1306-22. [PMID: 30768568 DOI: 10.1097/TP.0000000000002656] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
5 Gajos A, Tapper EB. The Role of Advanced Practice Providers in the Care of Nonalcoholic Fatty Liver Disease. Clin Ther 2021;43:518-23. [PMID: 33388173 DOI: 10.1016/j.clinthera.2020.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Szabo G, Kamath PS, Shah VH, Thursz M, Mathurin P; EASL-AASLD Joint Meeting. Alcohol-Related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for Further Study. Hepatology. 2019;69:2271-2283. [PMID: 30645002 DOI: 10.1002/hep.30369] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
7 Lee YS, Yoo YJ, Jung YK, Kim JH, Seo YS, Yim HJ, Kim IH, Lee SY, Kim BH, Kim JW, Lee CH, Yeon JE, Kwon SY, Um SH, Byun KS. Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2020;11:e00157. [PMID: 32251018 DOI: 10.14309/ctg.0000000000000157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
8 Lee DH, Sung SU, Lee YK, Lim IH, Jang H, Joo SK, Park JH, Chang MS, So YH, Kim W; Innovative Target Exploration of NAFLD (ITEN) Consortium. A sequential approach using the age-adjusted fibrosis-4 index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2022. [PMID: 35005800 DOI: 10.1111/apt.16766] [Reference Citation Analysis]
9 Kim TH, Lee Y, Lee YS, Gim JA, Ko E, Yim SY, Jung YK, Kang S, Kim MY, Kim H, Kim BH, Kim JH, Seo YS, Yim HJ, Yeon JE, Um SH, Byun KS. Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease. Sci Rep 2021;11:14639. [PMID: 34282172 DOI: 10.1038/s41598-021-94115-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Soon G, Wee A. Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective. Clin Mol Hepatol 2021;27:44-57. [PMID: 33207115 DOI: 10.3350/cmh.2020.0181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Lewindon PJ, Puertolas-lopez MV, Ramm LE, Noble C, Pereira TN, Wixey JA, Hartel GF, Calvopina DA, Leung DH, Ramm GA. Accuracy of Transient Elastography Data Combined With APRI in Detection and Staging of Liver Disease in Pediatric Patients With Cystic Fibrosis. Clinical Gastroenterology and Hepatology 2019;17:2561-2569.e5. [DOI: 10.1016/j.cgh.2019.03.015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
13 Mandala A, Janssen RC, Palle S, Short KR, Friedman JE. Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms. Nutrients 2020;12:E3166. [PMID: 33081177 DOI: 10.3390/nu12103166] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Hawksworth DJ, Burnett AL. Nonalcoholic Fatty Liver Disease, Male Sexual Dysfunction, and Infertility: Common Links, Common Problems. Sexual Medicine Reviews 2020;8:274-85. [DOI: 10.1016/j.sxmr.2019.01.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
15 Caussy C, Johansson L. Magnetic resonance-based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Endocrinol Diabetes Metab. 2020;3:e00134. [PMID: 33102797 DOI: 10.1002/edm2.134] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Yamamura S, Kawaguchi T, Nakano D, Tomiyasu Y, Yoshinaga S, Doi Y, Takahashi H, Anzai K, Eguchi Y, Torimura T, Shiba N. Profiles of advanced hepatic fibrosis evaluated by FIB‐4 index and shear wave elastography in health checkup examinees. Hepatol Res 2020;50:199-213. [DOI: 10.1111/hepr.13436] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
17 Hu Y, Wen Z. Validation and comparison of non-invasive prediction models based on liver stiffness measurement to identify patients who could avoid gastroscopy. Sci Rep 2021;11:150. [PMID: 33420233 DOI: 10.1038/s41598-020-80136-0] [Reference Citation Analysis]
18 Miele L, Zocco MA, Pizzolante F, De Matthaeis N, Ainora ME, Liguori A, Gasbarrini A, Grieco A, Rapaccini G. Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease. Metabolism 2020;112:154355. [DOI: 10.1016/j.metabol.2020.154355] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
19 Mantovani A, Sani E, Fassio A, Colecchia A, Viapiana O, Gatti D, Idolazzi L, Rossini M, Salvagno G, Lippi G, Zoppini G, Byrne C, Bonora E, Targher G. Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. Diabetes & Metabolism 2019;45:347-55. [DOI: 10.1016/j.diabet.2018.10.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
20 Balakrishnan M, Loomba R. The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD. J Clin Gastroenterol 2020;54:107-13. [PMID: 31789757 DOI: 10.1097/MCG.0000000000001284] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
21 Congly SE, Shaheen AA, Swain MG. Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting. PLoS One 2021;16:e0251741. [PMID: 34019560 DOI: 10.1371/journal.pone.0251741] [Reference Citation Analysis]
22 Fujii H, Kawada N, Japan Study Group Of Nafld Jsg-Nafld. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E3863. [PMID: 32485838 DOI: 10.3390/ijms21113863] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
23 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
24 Davyduke T, Tandon P, Al-Karaghouli M, Abraldes JG, Ma MM. Impact of Implementing a "FIB-4 First" Strategy on a Pathway for Patients With NAFLD Referred From Primary Care. Hepatol Commun 2019;3:1322-33. [PMID: 31592044 DOI: 10.1002/hep4.1411] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
25 Thursz M, Kamath PS, Mathurin P, Szabo G, Shah VH. Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study. Journal of Hepatology 2019;70:521-30. [DOI: 10.1016/j.jhep.2018.10.041] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 11.0] [Reference Citation Analysis]
26 Hou W, Janech MG, Sobolesky PM, Bland AM, Samsuddin S, Alazawi W, Syn WK. Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant/advanced fibrosis in patients with nonalcoholic fatty liver disease. Biosci Rep 2020;40:BSR20190395. [PMID: 31860081 DOI: 10.1042/BSR20190395] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
27 Al-Karaghouli M, Fuentes S, Davyduke T, Ma M, Abraldes JG. Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD. BMJ Open Gastroenterol 2022;9:e000798. [PMID: 34992072 DOI: 10.1136/bmjgast-2021-000798] [Reference Citation Analysis]
28 Wang JH, Ou HY, Yen YH, Chen CH, Lu SN. Usefulness of Controlled Attenuation Parameter in Detecting and Monitoring Hepatic Steatosis with MRI-PDFF as Reference. Dig Dis Sci 2020;65:1512-9. [PMID: 31617130 DOI: 10.1007/s10620-019-05883-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
29 Schreiner AD, Zhang J, Durkalski-Mauldin V, Livingston S, Marsden J, Bian J, Mauldin PD, Moran WP, Rockey DC. Advanced liver fibrosis and the metabolic syndrome in a primary care setting. Diabetes Metab Res Rev 2021. [PMID: 33759300 DOI: 10.1002/dmrr.3452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Tovo CV, Villela-Nogueira CA, Leite NC, Panke CL, Port GZ, Fernandes S, Buss C, Coral GP, Cardoso AC, Cravo CM, Calçado FL, Rezende GFM, Ferreira FC, Araujo-Neto JM, Perez RM, Moraes-Coelho HS, de Mattos AA. Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2019;18:445-9. [PMID: 31031166 DOI: 10.1016/j.aohep.2018.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
31 Viglino D, Martin M, Almeras N, Després JP, Coxson HO, Pépin JL, Vivodtzev I, Maltais F; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Low Liver Density Is Linked to Cardiovascular Comorbidity in COPD: An ECLIPSE Cohort Analysis. Int J Chron Obstruct Pulmon Dis 2019;14:3053-61. [PMID: 32099343 DOI: 10.2147/COPD.S233834] [Reference Citation Analysis]
32 Yu Y, Cai J, She Z, Li H. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. Adv Sci (Weinh). 2019;6:1801585. [PMID: 30828530 DOI: 10.1002/advs.201801585] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
33 Imajo K, Honda Y, Kobayashi T, Nagai K, Ozaki A, Iwaki M, Kessoku T, Ogawa Y, Takahashi H, Saigusa Y, Yoneda M, Kirikoshi H, Utsunomiya D, Aishima S, Saito S, Nakajima A. Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31673-6. [PMID: 33340780 DOI: 10.1016/j.cgh.2020.12.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
34 Pandita H, Mezey E, Ganapathy-Kanniappan S. Augmented Liver Uptake of the Membrane Voltage Sensor Tetraphenylphosphonium Distinguishes Early Fibrosis in a Mouse Model. Front Physiol 2021;12:676722. [PMID: 34759830 DOI: 10.3389/fphys.2021.676722] [Reference Citation Analysis]
35 Lambrecht J, Tacke F. Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease. Front Immunol 2020;11:634409. [PMID: 33633748 DOI: 10.3389/fimmu.2020.634409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
36 Long MT, Gandhi S, Loomba R. Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease. Metabolism 2020;111S:154259. [PMID: 32387227 DOI: 10.1016/j.metabol.2020.154259] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
37 Trujillo MJ, Chen J, Rubin JM, Gao J. Non-invasive imaging biomarkers to assess nonalcoholic fatty liver disease: A review. Clin Imaging 2021;78:22-34. [PMID: 33721575 DOI: 10.1016/j.clinimag.2021.02.039] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Huang D, Lin T, Wang S, Cheng L, Xie L, Lu Y, Chen M, Zhu L, Shi J. The liver fibrosis index is superior to the APRI and FIB-4 for predicting liver fibrosis in chronic hepatitis B patients in China. BMC Infect Dis 2019;19:878. [PMID: 31640590 DOI: 10.1186/s12879-019-4459-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
39 Schmitz SM, Kroh A, Koch A, Brozat JF, Stier C, Neumann UP, Ulmer TF, Alizai PH. Comparison of Liver Recovery After Sleeve Gastrectomy and Roux-en-Y-Gastric Bypass. Obes Surg 2021;31:3218-26. [PMID: 33813683 DOI: 10.1007/s11695-021-05390-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Imbault M, Dioguardi Burgio M, Faccinetto A, Ronot M, Bendjador H, Deffieux T, Triquet EO, Rautou P, Castera L, Gennisson J, Vilgrain V, Tanter M. Ultrasonic fat fraction quantification using in vivo adaptive sound speed estimation. Phys Med Biol 2018;63:215013. [DOI: 10.1088/1361-6560/aae661] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
41 Sango Solanas P, Tse Ve Koon K, Ratiney H, Millioz F, Caussy C, Beuf O. Harmonic wideband simultaneous dual-frequency MR Elastography. NMR Biomed 2021;34:e4442. [PMID: 33179393 DOI: 10.1002/nbm.4442] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Minamikawa T, Hase E, Ichimura-shimizu M, Morimoto Y, Suzuki A, Yasui T, Nakamura S, Tsutsui A, Takaguchi K, Tsuneyama K. Assessment of Ultra-Early-Stage Liver Fibrosis in Human Non-Alcoholic Fatty Liver Disease by Second-Harmonic Generation Microscopy. IJMS 2022;23:3357. [DOI: 10.3390/ijms23063357] [Reference Citation Analysis]
43 Gawrieh S, Wilson LA, Yates KP, Cummings OW, Vilar-Gomez E, Ajmera V, Kowdley KV, Rosenberg WM, Tonascia J, Chalasani N. Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial. Hepatol Commun 2021;5:786-97. [PMID: 34027269 DOI: 10.1002/hep4.1680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Du X, DeForest N, Majithia AR. Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities. Front Endocrinol (Lausanne) 2021;12:777075. [PMID: 34950105 DOI: 10.3389/fendo.2021.777075] [Reference Citation Analysis]
45 Wang Q, Xie W, Liu L, Wang P, Pan CQ. Serum markers for predicting advanced fibrosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease. Medicine (Baltimore) 2021;100:e25327. [PMID: 33950921 DOI: 10.1097/MD.0000000000025327] [Reference Citation Analysis]
46 Björkström K, Stål P, Holmer M, Bengtsson B, Staaf A, Hoffstedt J, Hagström H. A personalized treatment program in persons with type 2 diabetes is associated with a reduction in liver steatosis. Eur J Gastroenterol Hepatol 2021;33:1420-6. [PMID: 32796353 DOI: 10.1097/MEG.0000000000001882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Loomba R, Neuschwander-Tetri BA, Sanyal A, Chalasani N, Diehl AM, Terrault N, Kowdley K, Dasarathy S, Kleiner D, Behling C, Lavine J, Van Natta M, Middleton M, Tonascia J, Sirlin C; NASH Clinical Research Network. Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH. Hepatology 2020;72:1219-29. [PMID: 31965579 DOI: 10.1002/hep.31121] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
48 Loomba R, Lim JK, Patton H, El-Serag HB. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology 2020;158:1822-30. [PMID: 32006545 DOI: 10.1053/j.gastro.2019.12.053] [Cited by in Crossref: 49] [Cited by in F6Publishing: 60] [Article Influence: 24.5] [Reference Citation Analysis]
49 Furlan A, Tublin ME, Yu L, Chopra KB, Lippello A, Behari J. Comparison of 2D Shear Wave Elastography, Transient Elastography, and MR Elastography for the Diagnosis of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.AJR Am J Roentgenol. 2020;214:W20-W26. [PMID: 31714842 DOI: 10.2214/AJR.19.21267] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 7.7] [Reference Citation Analysis]
50 Byenfeldt M, Elvin A, Fransson P. Influence of Probe Pressure on Ultrasound-Based Shear Wave Elastography of the Liver Using Comb-Push 2-D Technology. Ultrasound Med Biol 2019;45:411-28. [PMID: 30401508 DOI: 10.1016/j.ultrasmedbio.2018.09.023] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
51 Liguori A, Ainora ME, Riccardi L, DE Matthaeis N, Pizzolante F, Gasbarrini A, Zocco MA, Grieco A, Rapaccini G, Miele L. The role of elastography in non-alcoholic fatty liver disease. Minerva Gastroenterol (Torino) 2021;67:164-70. [PMID: 34027933 DOI: 10.23736/S2724-5985.21.02801-4] [Reference Citation Analysis]
52 Sofias AM, De Lorenzi F, Peña Q, Azadkhah Shalmani A, Vucur M, Wang JW, Kiessling F, Shi Y, Consolino L, Storm G, Lammers T. Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders. Adv Drug Deliv Rev 2021;175:113831. [PMID: 34139255 DOI: 10.1016/j.addr.2021.113831] [Reference Citation Analysis]
53 Alhinai A, Qayyum-Khan A, Zhang X, Samaha P, Metrakos P, Deschenes M, Wong P, Ghali P, Chen TY, Sebastiani G. Non-alcoholic steatohepatitis in liver transplant recipients diagnosed by serum cytokeratin 18 and transient elastography: A prospective study. World J Hepatol 2021; 13(12): 2179-2191 [DOI: 10.4254/wjh.v13.i12.2179] [Reference Citation Analysis]
54 Le L, Kullar R, Saleh HM, Saab S. Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis. Dig Dis Sci 2020;65:3719-25. [PMID: 32671584 DOI: 10.1007/s10620-020-06382-4] [Reference Citation Analysis]
55 Li W. Non-Gaussian Diffusion MRI for Evaluating Hepatic Fibrosis. Acad Radiol 2022:S1076-6332(22)00267-7. [PMID: 35597754 DOI: 10.1016/j.acra.2022.04.020] [Reference Citation Analysis]
56 Sharpton SR, Tamaki N, Bettencourt R, Madamba E, Jung J, Liu A, Behling C, Valasek MA, Loomba R. Diagnostic accuracy of two-dimensional shear wave elastography and transient elastography in nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2021;14:17562848211050436. [PMID: 34646360 DOI: 10.1177/17562848211050436] [Reference Citation Analysis]
57 Sohn W, Chang Y, Cho YK, Hong YS, Shin H, Ryu S. Liver fibrosis scores and risk of liver-related mortality in young adults with chronic hepatitis B: A cohort study. J Viral Hepat 2021. [PMID: 34582599 DOI: 10.1111/jvh.13618] [Reference Citation Analysis]
58 Yoo JJ, Kim W, Kim MY, Jun DW, Kim SG, Yeon JE, Lee JW, Cho YK, Park SH, Sohn JH; the Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG). Recent research trends and updates on nonalcoholic fatty liver disease. Clin Mol Hepatol 2019;25:1-11. [PMID: 30086613 DOI: 10.3350/cmh.2018.0037] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
59 Hao X, Zeng Q. The Association and Interaction of Aldehyde Dehydrogenase 2 Polymorphisms with Food Group Intake and Probability of Having Non-Alcoholic Fatty Liver Disease. Diabetes Metab Syndr Obes 2020;13:5049-57. [PMID: 33376374 DOI: 10.2147/DMSO.S290491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Li L, Ye Y, Ran Y, Liu S, Tang Q, Liu Y, Liao X, Zhang J, Xiao G, Lu J, Zhang G, He Q, Hu S. A non-invasive model for predicting liver fibrosis in HBeAg-positive patients with normal or slightly elevated alanine aminotransferase. Medicine (Baltimore) 2021;100:e25581. [PMID: 33907107 DOI: 10.1097/MD.0000000000025581] [Reference Citation Analysis]